CG Oncology (CGON) News Today → AI's Next Magnificent Seven (From The Oxford Club) (Ad) Free CGON Stock Alerts $34.90 0.00 (0.00%) (As of 06/7/2024 08:51 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 8 at 8:42 AM | americanbankingnews.comCG Oncology (NASDAQ:CGON) Stock Price Down 5.1%June 6, 2024 | globenewswire.comCG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBCJune 2, 2024 | americanbankingnews.comCG Oncology (NASDAQ:CGON) Shares Gap Down to $34.29May 30, 2024 | marketbeat.comCG Oncology (NASDAQ:CGON) Trading 5% Higher CG Oncology (NASDAQ:CGON) Shares Up 5%May 28, 2024 | marketbeat.comCG Oncology's (CGON) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $75.00 price objective on shares of CG Oncology in a report on Tuesday.May 24, 2024 | msn.comCG Oncology climbs 10% on Phase 2 data for bladder cancer drugMay 24, 2024 | marketbeat.comCG Oncology (NASDAQ:CGON) Trading Up 5.1%CG Oncology (NASDAQ:CGON) Trading 5.1% HigherMay 24, 2024 | globenewswire.comCG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual MeetingMay 17, 2024 | marketbeat.comCG Oncology (NASDAQ:CGON) Trading Down 3.9%CG Oncology (NASDAQ:CGON) Trading Down 3.9%May 16, 2024 | marketbeat.comCG Oncology (NASDAQ:CGON) Trading Up 9.8%CG Oncology (NASDAQ:CGON) Shares Up 9.8%May 14, 2024 | markets.businessinsider.comDecoding 10 Analyst Evaluations For CG OncologyMay 14, 2024 | marketbeat.comCG Oncology (NASDAQ:CGON) Shares Gap Up to $25.84CG Oncology (NASDAQ:CGON) Shares Gap Up to $25.84May 14, 2024 | msn.comGoldman Sachs Upgrades CG Oncology (CGON)May 13, 2024 | marketbeat.comCG Oncology (NASDAQ:CGON) Stock Rating Upgraded by The Goldman Sachs GroupThe Goldman Sachs Group raised shares of CG Oncology from a "neutral" rating to a "buy" rating and set a $50.00 price target on the stock in a report on Monday.May 10, 2024 | markets.businessinsider.comBuy Rating for CG Oncology on Strong Trial Results and Market PotentialMay 10, 2024 | marketbeat.comCG Oncology (NASDAQ:CGON) Hits New 1-Year Low at $28.52CG Oncology (NASDAQ:CGON) Sets New 1-Year Low at $28.52May 9, 2024 | globenewswire.comCG Oncology Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 8, 2024 | marketbeat.comCG Oncology (NASDAQ:CGON) Trading Down 8.1%CG Oncology (NASDAQ:CGON) Shares Down 8.1%May 6, 2024 | markets.businessinsider.comCG Oncology’s Cretostimogene Shows Promising Efficacy and Safety in NMIBC Treatment, Merits Buy RatingMay 6, 2024 | seekingalpha.comCG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further ValueMay 6, 2024 | marketbeat.comCG Oncology (NASDAQ:CGON) Earns Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $75.00 target price on shares of CG Oncology in a research note on Monday.May 4, 2024 | markets.businessinsider.comBuy Rating Justified by CG Oncology’s Cretosmogene Efficacy and Market PositioningMay 3, 2024 | seekingalpha.comCG Oncology reports data from Phase 3 bladder cancer studyMay 3, 2024 | seekingalpha.comCG Oncology's Promising Bladder Cancer Treatment: Balancing Hope And Risk In Late-Stage TrialsMay 3, 2024 | globenewswire.comCretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder CancerMay 2, 2024 | marketbeat.comCG Oncology's (CGON) Overweight Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating and issued a $75.00 price objective on shares of CG Oncology in a research note on Thursday.April 26, 2024 | globenewswire.comCG Oncology to Host Virtual Investor Event on Friday, May 3, 2024April 25, 2024 | marketbeat.comFY2024 EPS Estimates for CG Oncology, Inc. Cut by Analyst (NASDAQ:CGON)CG Oncology, Inc. (NASDAQ:CGON - Free Report) - Equities research analysts at Lifesci Capital dropped their FY2024 earnings per share (EPS) estimates for shares of CG Oncology in a research note issued on Tuesday, April 23rd. Lifesci Capital analyst S. Slutsky now anticipates that the company wilApril 24, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - CGONApril 24, 2024 | globenewswire.comCG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024April 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for CG Oncology Amidst Bladder Cancer Treatment Landscape and BCG ShortageApril 23, 2024 | marketbeat.comCG Oncology (NASDAQ:CGON) Shares Up 7.9%CG Oncology (NASDAQ:CGON) Trading 7.9% HigherApril 16, 2024 | finance.yahoo.comCG Oncology, Inc. (CGON)April 15, 2024 | marketbeat.comCG Oncology (NASDAQ:CGON) Stock Price Down 6%CG Oncology (NASDAQ:CGON) Trading Down 6%April 12, 2024 | msn.com20 Countries with the Most Domestically Listed Companies in the WorldApril 8, 2024 | marketbeat.comEquities Analysts Set Expectations for CG Oncology, Inc.'s FY2024 Earnings (NASDAQ:CGON)CG Oncology, Inc. (NASDAQ:CGON - Free Report) - Stock analysts at HC Wainwright lifted their FY2024 earnings estimates for CG Oncology in a research report issued on Thursday, April 4th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($2.00) forApril 5, 2024 | marketbeat.comFY2028 EPS Estimates for CG Oncology, Inc. (NASDAQ:CGON) Raised by AnalystCG Oncology, Inc. (NASDAQ:CGON - Free Report) - Equities research analysts at HC Wainwright upped their FY2028 earnings per share estimates for CG Oncology in a report released on Thursday, April 4th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of $1.45 perApril 5, 2024 | investing.comCG Oncology Inc (CGON)April 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for CG Oncology on Strong Clinical Data and Market PotentialApril 4, 2024 | marketbeat.comCG Oncology's (CGON) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and set a $75.00 price target on shares of CG Oncology in a research report on Thursday.April 3, 2024 | marketbeat.comCG Oncology (NASDAQ:CGON) Stock Price Down 5.1%CG Oncology (NASDAQ:CGON) Trading Down 5.1%April 1, 2024 | markets.businessinsider.comBuy Rating Justified by CG Oncology’s Strong Clinical Trial Results and Promising Cretosimogene TherapyMarch 28, 2024 | globenewswire.comCG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual MeetingMarch 20, 2024 | marketbeat.comCG Oncology (NASDAQ:CGON) Shares Gap Down to $39.70CG Oncology (NASDAQ:CGON) Shares Gap Down to $39.70March 19, 2024 | marketbeat.comCG Oncology (NASDAQ:CGON) Stock Price Up 7.1%CG Oncology (NASDAQ:CGON) Stock Price Up 7.1%March 13, 2024 | marketbeat.comCG Oncology (NASDAQ:CGON) Trading Up 7.1%CG Oncology (NASDAQ:CGON) Trading 7.1% HigherMarch 1, 2024 | marketbeat.comCG Oncology (NASDAQ:CGON) Shares Down 3.9% CG Oncology (NASDAQ:CGON) Shares Down 3.9%March 1, 2024 | seekingalpha.comCGON CG Oncology, Inc.February 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for CG Oncology, Inc. on Promising CG0070 Phase 3 Trials and Unmet Medical NeedFebruary 27, 2024 | finance.yahoo.comCG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer Get CG Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CGON and its competitors with MarketBeat's FREE daily newsletter. Email Address No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free (Ad)Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analysis meets hedge fund-level market foresight! TRY "INVESTING IDEAS" TODAY CGON Media Mentions By Week CGON Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGON News Sentiment▼0.350.77▲Average Medical News Sentiment CGON News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGON Articles This Week▼23▲CGON Articles Average Week Get CG Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CGON and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Repligen News Today Vaxcyte News Today Revolution Medicines News Today Exelixis News Today Halozyme Therapeutics News Today CRISPR Therapeutics News Today Krystal Biotech News Today ImmunityBio News Today Immunovant News Today Denali Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGON) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored